Ubiquitin high affinity cyclic peptides and methods of use thereof
AssigneesTechnion Research & Development Foundation Limited, The University of Tokyo
InventorsAshraf BRIK, Mickal NAWATHA, Hiroaki SUGA, Joseph ROGERS
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a cyclic polypeptide having ubiquitin binding affinity (KD) of 0.1-100 nM. Further provided are methods for reducing deubiquitination activity of a cell, and for treating cancer in a subject in need thereof.
Claims13
A cyclic polypeptide comprising an amino acid sequence selected from the group consisting of:
- (SEQ ID NO:
- 4)
- LYLDDX1GDWWIC;
- (SEQ ID NO:
- 1)
- WYDX1EYYYLGYGC;
- (SEQ ID NO:
- 2)
- GWFDNLYWYVX1X1C;
- and
- (SEQ ID NO:
- 3)
- GWFDDX2YX3X4X5AYC;
- wherein X1 is an amino acid selected from:
- (i) naturally occurring amino acids;
- or (ii) non-naturally occurring amino acids, and wherein X2 is an amino acid selected from the group consisting of:
- Leu, Gln, Thr, Asn, Glu, and Asp, and wherein X3 is an amino acid selected from the group consisting of:
- Leu, and Tyr, and wherein X4 is an amino acid selected from the group consisting of:
- Phe and Tyr, and wherein X5 is an amino acid selected from the group consisting of:
- Val and Leu.
A method for ameliorating or treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a cyclic polypeptide, wherein said cyclic polypeptide binds ubiquitin with an affinity KD of 0.05-100 nM, wherein said cyclic polypeptide comprises not more than 16 amino acid residues, and wherein at least 55% of amino acids of said cyclic polypeptide are selected from the group consisting of:
- W, G, F, D, L, Y and C.
Dependencies are inferred from the claim text.